Re­gen­eron’s top sci­en­tist leads a hunt for genes to fend off dis­ease

A bil­lion­aire sci­en­tist stud­ies ge­netic mu­ta­tions to tar­get dis­ease

Bloomberg Businessweek (North America) - - The Global Tech -

Ge­orge Yan­copou­los is the chief sci­en­tific of­fi­cer at Re­gen­eron Phar­ma­ceu­ti­cals, which makes drugs that treat car­dio­vas­cu­lar dis­ease and vi­sion loss. (The vi­sion-loss drug Eylea has helped make the com­pany the best per­former on the S&P 500 over the past five years—and helped make Yan­copou­los rich.) Now, Re­gen­eron is se­quenc­ing the DNA of 250,000 vol­un­teers in an ef­fort to iden­tify and mimic mu­ta­tions that pro­tect against diseases rang­ing from high choles­terol to de­pres­sion. Treat­ments are be­ing de­vel­oped for asthma, arthri­tis, and os­teo­poro­sis. “There’s noth­ing bet­ter than sci­ence, noth­ing bet­ter than what we’re do­ing,” says Yan­copou­los, whose com­pany took over the na­tional Sci­ence Tal­ent Search com­pe­ti­tion from In­tel last month. “We’re just get­ting started.” <BW>

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.